I n the past decade, catheter ablation of atrial fibrillation (AF) has evolved as one of the most frequently performed procedures in tertiary arrhythmia centers worldwide. With the observation of the actively firing trigger originating from within the pulmonary veins (PVs), ablation strategies have focused at least in patients with paroxysmal AF on complete isolation of the PVs. 1, 2 However, wide area encircling lines around both the superior and inferior PVs (ipsilateral) were proven to be more effective than one-by-one PV isolation by several groups 3-6 but were first reported by the St. Georg group from Hamburg, Germany.
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In this edition of the journal, Metzner et al 7 report on the use of a second-generation cryoballoon, which potentially overcomes the shortcomings of the first-generation device. Although various groups reported an average first-procedure success rate of ≈60% in patients with paroxysmal AF, 8, 9 the second-generation balloon achieved an 81% success rate in this relatively small cohort of 50 patients from a single center. A reprocedure rate was not reported, but 26% of patients continued their medication to maintain in sinus rhythm. The clinical outcome assessed by serial Holter ECGs (and not by daily event monitoring as in similar studies from the same group) reveals on close examination that only 60.4% (26/43) of patients are in sinus rhythm and off drugs at the end of the follow-up. This is not significantly better than the previously reported results for the first-generation device. 8, 9 However, with the growing experience of the operators, procedure duration and fluoroscopy exposure have come down but are still higher than reported for radiofrequency ablations. The reason for the improvement in effectiveness is based on the overall lower temperatures achieved and the change in design that cools the frontal hemisphere rather than the whole balloon.
As with all novel devices, effectiveness is not the only important marker but safety is paramount, especially before a given device is made available to a larger (and possibly less experienced) group of operators. A good example of this caveat is the recent experience of the same Hamburg group with the highintensity focused ultrasound balloon. Initially reported to be highly effective in creating a single-shot PV isolation, 10 some patients died of atrioesophageal fistulas. The then added safety feature of intraesophageal temperature measurements was promoted to tame the energy and to continue the investigation of this novel energy, only to learn subsequently that the defined cutoff value was useless in avoiding this potentially fatal complication. 11 Metzner et al 7 are now proposing a similar safety feature based on continuous temperature monitoring in the esophagus, this time during cryoenergy PV isolation. Using serial endoscopies after the ablation procedure, they defined a safe cutoff value of 10°C. Besides the fact that it seems imprudent to define this value on a relatively small number of patients (total of 50 in this study), there are also some simple anatomic basics to consider. The esophagus in its' inactive state is a very flexible muscular sleeve that is folded, ready to extend and move with every swallowing action even in deeply sedated patients. 12 The location of the temperature probe can at best be controlled in the craniocaudal orientation but not actively laterally. This excludes active navigation of this probe into the closest position to any type of balloon or ablation catheter. 13, 14 Any temperature measured that is not at the closest proximity will inadvertently measure a higher temperature, implying a safe application (Figure) . However, areas closer to the balloon might still be at risk of getting too cool. Excessive hypothermia is a clear indication of a lesion extending beyond the atrial myocardium. A higher temperature is only a marker of a temperature probe being potentially too far away. Given the anatomic location of the inferior PVs both pointing in a more posterior direction (rather than laterally) closer to the esophagus, this finding illustrates again the inability of the esophageal temperature probe to be positioned in all cases at the closest possible location.
Although it is good to see that only 4% of the patients had a phrenic nerve lesion (rather than the previous >10%), 8, 9 this might not be the end of this complication either. The authors seemed to be somewhat surprised about the late phrenic lesion in the second patient, but why should cryolesions not be able to mature as much as radiofrequency lesions can? The second-generation balloon still needs to be firmly opposed to the PV ostium, and the safety measure of constant pacing above the balloon has not been changed, while deeper lesions are achieved. Because the authors still advocate omitting 3-dimensional (3D) imaging or at least localizing the right phrenic nerve in 3D (a technique they had introduced earlier), 15 this avoidable complication is likely to continue.
Coming all the way from demonstrating that the larger ipsilateral PV isolation has a better outcome than one-by-one PV isolation, and that line completeness is important for clinical success, it seems surprising that the St. Georg group from Hamburg now advocates so forcefully single PV isolation approaches. The shear ability or availability of a novel device or energy does not make it a good choice, and lessons learned from systematic previous studies should not be forgotten. Figure. Left, The ideally positioned esophageal temperature probe (yellow) in closest possible proximity, which is able to measure the area cooled by the freeze (light blue fan around the blue cryoballoon positioned at the ostium of the lateral inferior pulmonary vein). Right, A more likely situation where the temperature probe is not in closest proximity. Areas of the esophagus can be cooled below the safety threshold and might be damaged despite safe temperatures. LA indicates left atrium; LAA, left atrial appendage; LSPV, left superior pulmonary vein; RIPV, right inferior pulmonary vein; and RSPV, right superior pulmonary vein.
